Demographics | |
Age, years | 55±12 |
Female, n (%) | 42 (86) |
Disease characteristics | |
RA duration, years | 9.8 (4.1–18.5) |
DAS28 score | 5.7±1.3 |
ESR, mm/h | 23 (10–46) |
CRP, mg/l | 15 (3–30) |
IgM RF positive, % | 34 (71) |
ACPA positive, % | 36 (75) |
Erosive disease, % | 35 (73) |
Medication | |
Previous biologicals, n | 2 (1–2) |
>1 biological in history, n (%) | 25 (52) |
Previous DMARDS, n | 3.9±1.4 |
Current prednisolone use, n (%) | 35 (73) |
Prednisolone dosage, mg/day | 7.5 (0–10) |
Current MTX use, n (%) | 30 (63) |
MTX dosage, mg/week | 13.8 (0–25) |
Current SSZ use, n (%) | 9 (19) |
Current HCQ use, n (%) | 10 (21) |
Other characteristics | |
Body mass index, kg/m2 | 26.9±6.1 |
Smoking, n (%) | 26 (57) |
Diabetes mellitus, n (%) | 6 (12) |
Thyroid disease, n (%) | 4 (8) |
Lipid lowering drugs, n (%) | 7 (14) |
Continuous variables are presented as mean with SD or median with IQR when appropriate.
ACPA, anticyclic citrullinated protein; CRP, C reactive protein; DAS28, 28 joint disease activity score; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HCQ, hydroxychloroquine; IgM, immunoglobulin M; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SSZ, sulphasalazyne.